We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC APPROVES TEVA-BMS DEAL ON GENERIC PARAPLATIN
FTC APPROVES TEVA-BMS DEAL ON GENERIC PARAPLATIN
May 28, 2004
Teva Pharmaceutical will get nearly a four-month jump on launching a generic version of BMS’ cancer drug Paraplatin now that the FTC has signed off on a deal between Bristol-Myers Squibb (BMS) and Teva.
The FTC’s May 24 advisory opinion, released last week, lets Teva start marketing the BMS-authorized product June 24.